Friday, 6 November 2026European Markets

AXWAY SOFTWARE Stock Bullish By 32% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AXWAY SOFTWARE (CAC 40: AXW.PA) jumped by a staggering 32.55% in 21 sessions from $17.05 to $22.60 at 16:53 EST on Tuesday, following the last session's upward trend. CAC 40 is falling 0.07% to $7,132.35, following the last session's downward trend.

About AXWAY SOFTWARE

Axway Software SA operates as an infrastructure software publisher in the Americas, France, rest of Europe, the Asia Pacific, and internationally. The company provides AMPLIFY, a platform that offers application integration, API management, managed file transfer, B2B-EDI integration, and digital finance solutions. It also offers specialized enterprise integration products to provide visibility, intelligence, and security throughout the digital ecosystem; counter threats before they happen; optimize business assets and resources; safeguard against risks; and improve operational performance, as well as provides managed cloud services. The company serves the automotive, banking and financial services, healthcare, insurance, life science, manufacturing and consumer packaged goods, retail, and transportation and logistics industries, as well as government and public sectors. Axway Software SA was incorporated in 2000 and is headquartered in Scottsdale, Arizona.

Earnings Per Share

As for profitability, AXWAY SOFTWARE has a trailing twelve months EPS of $0.46.

PE Ratio

AXWAY SOFTWARE has a trailing twelve months price to earnings ratio of 49.13. Meaning, the purchaser of the share is investing $49.13 for every dollar of annual earnings.

More news about AXWAY SOFTWARE (AXW.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com